0756 GMT - Roche delivered solid results in line with expectations but its diagnostics' profitability disappoints, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's core EBIT of its diagnostics unit missed Vontobel's estimates by 10.5% which surprises as only 1Q was still affected by the pandemic washout, the analyst says. Its 2025 guidance is conservative, unchanged under the new management, he adds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 30, 2025 02:56 ET (07:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.